 Outlook Therapeutics NASDAQ:OTLK Inc said it has submitted its Biologics License Application BLA to the US Food and Drug Administration FDA for ONS-5010, an investigational therapy for the treatment of wet age-related macular degeneration wet AMD. If approved, the treatment will be branded as LYTENAVA bevacizumab-vikg and could replace the current practice of using unapproved repackaged IV bevacizumab sourced from compounding pharmacies, products that have known risks of contamination and inconsistent potency and availability. 